Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Abstract

To investigate the efficacy and safety of CVT-301 in treating motor fluctuation in patients with Parkinson disease (PD). This study demonstrated that the CVT-301 group had a higher proportion of patients achieving an ON state than the placebo group (odds ratio [OR] = 2.68; 95% confidence interval [CI]: 1.86-3.86; p < 0.00001). Moreover, CVT-301 had also shown to improve motor function by Unified Parkinson Disease Rating Scale part III score (standardized mean difference = 3.83; 95% CI: 2.44-5.23; p < 0.00001) and promote an overall improvement of PD by Patient Global Impression of Change self-rating (OR = 2.95; 95% CI: 1.78-4.9; p < 0.00001). The most common adverse events encountered were respiratory symptoms (OR = 12.18; 95% CI: 5.01-29.62; p < 0.00001) and nausea (OR = 3.95; 95% CI: 1.01-15.41; p = 0.05). CVT-301 had the potential to be an alternative or even a preferred treatment for motor fluctuation in patients with PD.